Alternative beliefs in psychedelic drug users.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 09 2023
Historique:
received: 18 09 2022
accepted: 10 09 2023
medline: 5 10 2023
pubmed: 1 10 2023
entrez: 30 9 2023
Statut: epublish

Résumé

Previous research has suggested that classical psychedelics can foster significant and enduring changes in personality traits and subjective wellbeing. Despite the lack of evidence for adverse effects on mental health stemming from psychedelic use, concerns persist regarding the capacity of these substances to modulate information processing and attitudes towards factual data. The aim of the present study was to investigate the propensity for accepting alternative facts and the general treatment of knowledge within a sample of 392 participants, 233 of whom reported at least a single incidence of psychedelic use in their lifetime. To do this, we leveraged step-wise methods of linear modelling investigating effects of demographics, psychiatric conditions and concomitant drug use. Our findings revealed a moderate positive association between psychedelic use and beliefs in alternative facts, as well as the specific belief that facts are politically influenced. However, no links were found for favouring intuition over evidence when confirming facts. Among other investigated drugs, only alcohol was negatively associated with beliefs in alternative facts. Taken together, our results support the link between psychedelic use and non-conformist thinking styles, which can be attributed to the psychological effects of the drugs themselves, but may also mirror a common trait related to unconventional beliefs and illicit substance use.

Identifiants

pubmed: 37777572
doi: 10.1038/s41598-023-42444-z
pii: 10.1038/s41598-023-42444-z
pmc: PMC10542757
doi:

Substances chimiques

Hallucinogens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16432

Informations de copyright

© 2023. Springer Nature Limited.

Références

Pharmacol Rev. 2016 Apr;68(2):264-355
pubmed: 26841800
Eur J Public Health. 2014 Aug;24(4):572-7
pubmed: 24473595
Ann Clin Psychiatry. 2006 Jul-Sep;18(3):145-8
pubmed: 16923651
Curr Drug Abuse Rev. 2014;7(3):157-64
pubmed: 25563443
J Autism Dev Disord. 2011 Aug;41(8):1076-89
pubmed: 21086033
Psychol Med. 2005 Feb;35(2):245-56
pubmed: 15841682
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Ther Adv Psychopharmacol. 2023 May 29;13:20451253231172254
pubmed: 37284524
PLoS One. 2017 Sep 18;12(9):e0184733
pubmed: 28922387
J Abnorm Psychol. 2015 Aug;124(3):660-73
pubmed: 25844684
Sci Rep. 2021 Nov 23;11(1):22166
pubmed: 34815421
Int J Environ Res Public Health. 2019 Dec 16;16(24):
pubmed: 31888300
Pers Soc Psychol Bull. 2020 Aug;46(8):1234-1246
pubmed: 31928312
J Pers Soc Psychol. 2020 May;118(5):900-918
pubmed: 31904251
Psychol Med. 2020 Dec;50(16):2655-2666
pubmed: 33143790
Front Psychol. 2013 Apr 30;4:225
pubmed: 23641227
Vaccine. 2010 Feb 17;28(7):1709-16
pubmed: 20045099
Soc Sci Med. 2006 Feb;62(3):628-42
pubmed: 16039769
PLoS One. 2019 Dec 3;14(12):e0225964
pubmed: 31794581
J Psychoactive Drugs. 2017 Jul-Aug;49(3):182-191
pubmed: 28443703
N Engl J Med. 2022 Nov 3;387(18):1637-1648
pubmed: 36322843
Psychol Med. 2016 May;46(7):1379-90
pubmed: 26847689
Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92
pubmed: 16826400
Br J Clin Psychol. 1998 Feb;37(1):107-8
pubmed: 9547965
PLoS One. 2017 Mar 3;12(3):e0171238
pubmed: 28257506
Soc Sci Med. 2005 Sep;61(6):1151-8
pubmed: 15970227
PLoS One. 2014 Feb 20;9(2):e89177
pubmed: 24586574
Lancet Psychiatry. 2016 Jul;3(7):619-27
pubmed: 27210031
PLoS One. 2012;7(2):e31500
pubmed: 22347487
Alcohol Alcohol. 2005 Nov-Dec;40(6):556-62
pubmed: 16087659
Health Econ Rev. 2016 Dec;6(1):3
pubmed: 26753688
Schizophr Bull. 2004;30(4):1005-22
pubmed: 15954204
Front Psychol. 2019 Feb 11;10:205
pubmed: 30853921
J Psychopharmacol. 2015 Mar;29(3):289-99
pubmed: 25586396
J Pers. 2021 May;89(3):422-436
pubmed: 32852781
Exp Clin Psychopharmacol. 2002 Nov;10(4):425-34
pubmed: 12498340
Psychol Bull. 2010 Sep;136(5):768-821
pubmed: 20804236
Cereb Cortex. 2012 Oct;22(10):2354-64
pubmed: 22079921
Nat Med. 2021 Jun;27(6):1025-1033
pubmed: 33972795
Sci Rep. 2021 Jul 23;11(1):15058
pubmed: 34301969
Addiction. 2005 Apr;100(4):562-3
pubmed: 15784073
Hum Brain Mapp. 2016 Sep;37(9):3203-13
pubmed: 27151536
J Psychopharmacol. 2011 Nov;25(11):1453-61
pubmed: 21956378
Psychol Bull. 1996 Nov;120(3):323-37
pubmed: 8900080
J Psychopharmacol. 2018 Jul;32(7):811-819
pubmed: 29338538
J Psychopharmacol. 2015 Jan;29(1):57-68
pubmed: 25389218

Auteurs

Alexander V Lebedev (AV)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. alexander.lebedev@ki.se.
Center for Cognitive and Computational Neuroscience, Karolinska Institutet, Stockholm, Sweden. alexander.lebedev@ki.se.

Kasim Acar (K)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Center for Cognitive and Computational Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Otilia Horntvedt (O)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Andrés E Cabrera (AE)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Otto Simonsson (O)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institute, Stockholm, Sweden.

Walter Osika (W)

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institute, Stockholm, Sweden.

Martin Ingvar (M)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Center for Cognitive and Computational Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Predrag Petrovic (P)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Center for Cognitive and Computational Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH